Caliper Life Sciences, Inc. (CALP) Tops Q2 EPS by 4c, Posts Q3 and FY11 Revenue Guidance
Tweet
Share
E-mailGet Alerts CALP Hot Sheet
Price: $10.49 --0%
Financial Fact:
License fees and contract revenue: 3.92M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
License fees and contract revenue: 3.92M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Caliper Life Sciences, Inc. (NASDAQ: CALP) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $34.39 million.
Caliper Life Sciences, Inc. sees Q3 2011 revenue of $33-$36 million, versus the consensus of $34.72 million.
Caliper Life Sciences, Inc. sees FY2011 revenue of $146-$152 million, versus the consensus of $144.01 million.
Caliper Life Sciences, Inc. sees Q3 2011 revenue of $33-$36 million, versus the consensus of $34.72 million.
Caliper Life Sciences, Inc. sees FY2011 revenue of $146-$152 million, versus the consensus of $144.01 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
